Patents by Inventor RONALD KANE

RONALD KANE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOURNIQUET DRESSING SLEEVE FOR DIGITS
    Publication number: 20100100025
    Abstract: A tourniquet dressing sleeve for digits is made from a sleeve preferably non-Latex polymeric stretchable material layered with a covering layer of stretchable woven fabric then folded over upon itself to form a sleeve with the edges sewn together to form a flexible, stretchable compression sleeve to fit around digits to exsanguinate them.
    Type: Application
    Filed: October 17, 2008
    Publication date: April 22, 2010
    Inventor: RONALD KANE
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Patent number: 7384925
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: June 10, 2008
    Assignees: OXiGENE, Inc., Baylor University
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Patent number: 6919324
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: July 19, 2005
    Assignees: Oxigene, Inc., Baylor University
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Publication number: 20030149003
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Application
    Filed: October 28, 2002
    Publication date: August 7, 2003
    Inventors: David J. Chaplin, Charles Manly Garner, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Patent number: RE45720
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: October 6, 2015
    Assignees: OXiGENE, Inc., Baylor University
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Patent number: RE45907
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: March 1, 2016
    Assignees: OXiGENE, Inc., Baylor Universwity
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
  • Lawn repair device
    Patent number: D901995
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: November 17, 2020
    Assignee: Seederator, LLC
    Inventors: Ronald Kane, Jason Nadeau, Jordan Nadeau